Reduction of venous thromboembolism following prolonged prophylaxis with the low molecular weight heparin Certoparin after endoprothetic joint replacement or osteosynthesis of the lower limb in elderly patients

Thrombosis and Haemostasis

Volumn 90, Issue 6, 2003, Pages 1100-1105

  Kolb, Gerald ^a   Bodamer, Iris ^a   Galster, Heide ^a   Seidlmayer, Christoph ^a   Grambach, Konrad ^b   Koudela, Karel ^c   Eisele, Ralf R ^d   Becker, Clemens ^e   Paal, Valerie ^a   Spannagel, Uwe ^f   Brom, Joachim ^f   Weidinger, Gottfried ^f  

^a ST BONIFATIUS HOSPITAL   (Germany)

^b Elisabeth Hospital   (Germany)

^c CHARLES UNIVERSITY   (Czech Republic)

^d UNIVERSITY HOSPITAL ULM   (Germany)

^e Bethesda Geriatrische Klinik Ulm gGmbH   (Germany)

^f Clinical Research and Development   (Germany)

Author keywords

Low molecular weight heparin; Orthopedic surgery; Prolonged prophylaxis; Venous thromboembolism

Indexed keywords

CERTOPARIN; D DIMER; FIBRIN MONOMER; LOW MOLECULAR WEIGHT HEPARIN; MONOEMBOLEX; PLACEBO;

AGED; ARTICLE; BLEEDING DISORDER; BLOOD CLOTTING PARAMETERS; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DOUBLE BLIND PROCEDURE; DRUG FATALITY; ECHOGRAPHY; ELDERLY CARE; FEMALE; FEMUR HEAD PROSTHESIS; HEMORRHOID; HIGH RISK PATIENT; HIP ARTHROPLASTY; HUMAN; JOINT PROSTHESIS; KNEE ARTHROPLASTY; LEG PROSTHESIS; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORTHOPEDIC SURGERY; OSTEOSYNTHESIS; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROPHYLAXIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SCREENING; STATISTICAL SIGNIFICANCE; SYMPTOMATOLOGY; VENOUS THROMBOEMBOLISM;

EID: 0346903203     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/th03-01-0062     Document Type: Article

References (26)

1. Nurmohamed MT, Rosendaal FR, Büller HR, et al. Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: A meta-analysis. Lancet 1992; 340: 152-6.
2. Leizorovicz A, Haugh MC, Chapuis FR, et al. Low molecular weight heparin in prevention of perioperative thrombosis. Br Med J 1992; 305: 913-20.
3. Howard AW, Aaron SD. Low molecular weight heparin decreases proximal and distal deep venous thrombosis following total knee arthroplasty. A meta-analysis of randomized trials. Thromb Haemost 1998; 79: 902-6.
4. Koch A, Ziegler S, Breitschwerdt H, et al. Low molecular weight heparin and unfractionated heparin in thrombosis prophylaxis: Meta-analysis based on original patient data. Thromb Res 2001; 102: 295-309.
5. McCahill JP, Carrington RWJ, Skinner JA. Current concepts in venous thromboembolism and major lower limb orthopaedic surgery. Int J Clin Pract 2002; 56: 292-7.
6. Weitz JL. Low-molecular-weight heparins. N Engl J Med 1997; 337: 688-98.
7. Hirsh J, Warkentin TE, Raschke R, et al. Heparin and low-molecular-weight heparin. Mechanisms of action, pharmacokinetics, dosing, considerations, monitoring, efficacy, and safety. Chest 1998; 114 (Suppl): 489S-510S.
8. Geerts WH, Heit JA, Clagett GP, et al. Prevention of thromboembolism. Chest 2001; 119: 132S-75S.
9. Huber O, Bounameaux H, Borst F, et al. Postoperative pulmonary embolism after hospital discharge. An underestimated risk. Arch Surg 1992; 127: 310-3.
10. Dahl OE, Aspelin T, Arnesen H, et al. Increased activation of coagulation and formation of late deep venous thrombosis following discontinuation of thromboprophylaxis after hip replacement surgery. Thromb Res 1995; 80: 299-306.
11. Galster H, Kolb G, Kohsytorz A, et al. The pre-, peri-, and postsurgical activation of coagulation and the thromboembolic risk for different risk groups. Thromb Res 2000; 100: 381-8.
12. Bergqvist D, Benoni G, Björgell O, et al. Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. N Engl J Med 1996; 335: 696-700.
13. Planes A, Vochelle N, Darmon J-Y, et al. Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: Double-blind randomised comparison of enoxaparin versus placebo. Lancet 1996; 348: 224-8.
14. Dahl OE, Andreassen G, Aspelin T, et al. Prolonged thromboprophylaxis following hip replacement surgery - Results of a double-blind, prospective, randomised, placebo-controlled study with dalteparin (Fragmin®). Thromb Haemost 1997; 77: 26-31.
15. Lassen MR, Borris LC, Anderson BS, et al. Efficacy and safety of prolonged thromboprophylaxis with a low molecular weight heparin (dalteparin) after total hip arthrosplasty - The Danish prolonged prophylaxis (DaPP) the Danish prolonged prophylaxis (DaPP) study. Thromb Res 1998; 89: 281-7.
16. Hull RD, Pineo GF, Francis C, et al. Low-molecular-weight heparin prophylaxis using dalteparin extended out-of-hospital vs in-hospital warfarin/out-of-hospital placebo in hip arthroplasty patients. Arch Intern Med 2000; 160: 2208-15.
17. Comp PC, Spiro TE, Friedman RJ, et al. for the Enoxaparin Clinical Trial Group. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. Enoxaparin clinical trial group. J Bone Joint Surg 2001; 83-A: 336-45.
18. Bauer P, Köhne K. Evaluation of experiments with adaptive interim analysis. Biometrics 1994; 50: 1029-41.
19. Eriksson BI, Wille-Jørgensen P, Kälebo P, et al. A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement. N Engl J Med 1997; 337: 1329-35.
20. Lassen MR, Bauer KA, Eriksson BI, et al. for the European Pentasaccharide Hip Elective Surgery Study (EPHESUS) Steering Committee. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery. A randomised double-blind comparison. Lancet 2002; 359: 1715-20.
21. Heijboer H, Cogo A, Buller HR, et al. Detection of deep-vein thrombosis with impedance plethysmography and real-time compression ultrasonography in hospitalized patients. Arch Intern Med 1992; 152: 1901-3.
22. Kearon C, Julian JA, Newman BA, et al. Noninvasive diagnosis of deep venous thrombosis. Ann Intern Med 1998; 128: 663-77.
23. Cohen AT, Bailey CS, Alikhan R, et al. Extended thromboprophylaxis with low molecular weight heparin reduces symptomatic venous thromboembolism following lower limb arthroplasty - A meta-analysis. Thromb Haemost 2001; 85: 940-1.
24. Eikelboom JW, Quinlan DJ, Douketis JD. Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: A meta-analysis of the randomised trials. Lancet 2001; 358: 9-15.
25. Lowe GDO. Prediction of postoperative deep-vein thrombosis. Thromb Haemost 1997; 78: 47-52.
26. Lowe GDO, Haverkate F, Thompson SG, et al. on behalf of the ECAT DVT Study Group. Prediction of deep vein thrombosis after elective hip replacement surgery by preoperative clinical and haemostatic variables: The ECAT DVT Study. Thromb Haemost 1999; 81: 879-86.